Antisense inhibition of e2f transcription factor 1 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsIan Popoff, Vickie L. Brown-Driver, Lex M. Cowsert
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 1. Methods of using these compounds for modulation of E2F transcription factor 1 expression and for treatment of diseases associated with expression of E2F transcription factor 1 are provided.
Claims13
An antisense compound up to 30 nucleobases in length targeted to a nucleic acid molecule encoding E2F transcription factor 1, wherein said antisense compound specifically hybridizes with and inhibits the expression of E2F transcription factor 1 and wherein said antisense compound has a sequence comprising at least an 8 nucleobase portion of SEQ ID NO:
- 14, 19, 22, 23, 24, 25, 26, 30, 31, 33, 34, 36, 38, 39, 40, 41, 42, 44, 45, 49, 50, 51, 52, 54, 56, 57, 58, 60, 61, 62, 63, 64, 66, 67, 68, 69, 73, 74, 75, 77, 79, 81, 83, 84, 85, 86, 87, or 88.
Dependencies are inferred from the claim text.